DIANA CHOW to Riluzole
This is a "connection" page, showing publications DIANA CHOW has written about Riluzole.
Connection Strength
2.266
-
Rational design and development of a stable liquid formulation of riluzole and its pharmacokinetic evaluation after oral and IV administrations in rats. Eur J Pharm Sci. 2018 Dec 01; 125:1-10.
Score: 0.615
-
UPLC-MS/MS assay of riluzole in human plasma and cerebrospinal fluid (CSF): Application in samples from spinal cord injured patients. J Pharm Biomed Anal. 2017 Nov 30; 146:334-340.
Score: 0.573
-
Pharmacology of riluzole in acute spinal cord injury. J Neurosurg Spine. 2012 Sep; 17(1 Suppl):129-40.
Score: 0.405
-
Riluzole in Spinal Cord Injury Study (RISCIS)-Pharmacokinetic (PK) Sub-Study: An Analysis of Pharmacokinetics, Pharmacodynamics, and Impact on Axonal Degradation of Riluzole in Patients With Traumatic Cervical Spinal Cord Injury Enrolled in the RISCIS Phase III Randomized Controlled Trial. J Neurotrauma. 2023 09; 40(17-18):1889-1906.
Score: 0.217
-
Longitudinal Impact of Acute Spinal Cord Injury on Clinical Pharmacokinetics of Riluzole, a Potential Neuroprotective Agent. J Clin Pharmacol. 2021 09; 61(9):1232-1242.
Score: 0.187
-
A prospective, multicenter, phase I matched-comparison group trial of safety, pharmacokinetics, and preliminary efficacy of riluzole in patients with traumatic spinal cord injury. J Neurotrauma. 2014 Feb 01; 31(3):239-55.
Score: 0.109
-
Delayed post-injury administration of riluzole is neuroprotective in a preclinical rodent model of cervical spinal cord injury. J Neurotrauma. 2013 Mar 15; 30(6):441-52.
Score: 0.105
-
Safety and Efficacy of Riluzole in Acute Spinal Cord Injury Study (RISCIS): A Multi-Center, Randomized, Placebo-Controlled, Double-Blinded Trial. J Neurotrauma. 2023 09; 40(17-18):1878-1888.
Score: 0.054